EUVIMEDEUVIMED entdecken
Crossref

Phosphodiesterase-5 Inhibitors and Dementia Risk: Confounding by Indication in Real-World Studies

Che-Yuan Wu, Walter Swardfager

Journal of Alzheimer’s Disease · 2024

DOI: 10.3233/jad-240520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Che-Yuan Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Dementia, Phosphodiesterase 5 Inhibitors. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacoepidemiologic studies using routinely collected data allow researchers to propose drugs for repurposing trials for dementia prevention or treatment. A recent cohort study reported a 54% lower dementia risk among users of sildenafil compared to users of certain cardiovascular medications. We caution that “confounding by indication” can arise when outcomes are compared between a drug of interest and an inappropriate comparator. Here, we emphasize important considerations in selecting an active comparator. We assess the implications of substantial risk of confounding by indication in pharmacoepidemiologic studies linking phosphodiesterase-5 inhibitors to lower dementia risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DementiaPhosphodiesterase 5 InhibitorsHumansConfounding Factors, EpidemiologicPharmacoepidemiologySildenafil Citrate

Stichwörter der Autor:innen

Alzheimer’s diseaseconfounding by indicationdementiapharmacoepidemiologyphosphodiesterase-5 inhibitors

Substanzen

Phosphodiesterase 5 InhibitorsSildenafil Citrate

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
  • Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.

Zitieren

APA

Wu, C. Y., & Swardfager, W. (2024). Phosphodiesterase-5 Inhibitors and Dementia Risk: Confounding by Indication in Real-World Studies. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-240520

Vancouver

Wu CY, Swardfager W. Phosphodiesterase-5 Inhibitors and Dementia Risk: Confounding by Indication in Real-World Studies. Journal of Alzheimer’s Disease. 2024. doi:10.3233/jad-240520

BibTeX
@article{Wu2024,
  author = {Wu, Che-Yuan and Swardfager, Walter},
  title = {Phosphodiesterase-5 Inhibitors and Dementia Risk: Confounding by Indication in Real-World Studies},
  journal = {Journal of Alzheimer’s Disease},
  year = {2024},
  doi = {10.3233/jad-240520}
}
Kostenlos starten →